Zhen Li, ADARx Pharmaceuticals CEO
May 14, 2025 09:00 AM EDTUpdated 11:08 AM
Startups
Deals
Pharma

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

Kyle LaHucik

Senior Reporter

Ab­b­Vie is beef­ing up its pres­ence in the buzzy field of siR­NAs by ink­ing a deal with ADARx Phar­ma­ceu­ti­cals. Ab­b­Vie last year spent $1.4 bil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

Ad­vo­ca­cy groups and ex­perts call for decade-long ban on germline edit­ing

CRISPR patent spat re­vived by fed­er­al ap­peals court rul­ing

Bay­er starts 2025 by cut­ting 2,000 jobs as it homes in on year-end re­haul tar­get

SK, Car­lyle bol­ster blue­bird bio bid; Theri­ni Bio rais­es $39M

A service from the Financial Times